Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Durvalumab Consolidation in Stage III NSCLC
NCT05757843Phase 2Withdrawn
- Sponsor
- Indiana University
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Indiana University. Primary endpoint: Progression-Free Survival at 24 months. Planned start Sep 2024; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05757843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757843.